In late November Abbott—one of Dexcom’s main competitors— recalled some of its CGMs due to inaccurate low glucose readings.

When it comes to the diabetes space, Dexcom is one of the heavy hitters. Its work in the continuous glucose monitoring space has put it on the map. In 2018, its Dexcom G6, an integrated continuous ...

DexCom, Inc.'s growth is impressive but limited by its niche market, with my projected ceiling being ~$7.5bn in peak annual revenues. Despite positive Q4 2024 results, DexCom's stock is fairly valued, ...

Researchers who use Fitabase to capture data from Fitbit and Garmin devices will soon be able to capture a new kind of data: continuous glucose monitoring data from Dexcom products. The ability to ...

DexCom Q4 revenue beat at $1.114B, up 8% Y/Y, but EPS missed at $0.45 vs. $0.50 consensus. FY25 guidance reaffirmed with $4.6B revenue target and 21% operating margin. Get stock picks, daily rankings, ...

Dexcom has received FDA approval for a continuous glucose monitor (CGM) that integrates with insulin pumps and other diabetes devices. The regulatory clearance marks the first time the FDA has signed ...

Eli Lilly and Company LLY announced that it has inked a development deal with DexCom, Inc. DXCM to integrate the latter’s continuous glucose monitoring (CGM) products and tools into Lilly’s Connected ...

Dexcom posted FY19 sales expectations on Monday and they are even better than the company forecast in Q3 at $1.47bn - a 42% year-on-year increase. Company drove revenues by 49% year-on-year in Q3 to ...

Morgan Stanley analyst Patrick Wood upgraded the stock to Overweight from Equal Weight on Tuesday, citing a favorable ...

After what the diabetes data company has described as its best year ever, Dexcom is starting to spend its extra cash—first on its inaugural Super Bowl ad, and now to launch its very own venture ...